Search by Drug Name or NDC
NDC 49884-0151-54 Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride 140; 125; 125 mg/1; mg/1; mg/1 Details
Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride 140; 125; 125 mg/1; mg/1; mg/1
Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Par Pharmaceutical, Inc.. The primary component is BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE.
MedlinePlus Drug Summary
Bismuth, metronidazole, and tetracycline is used along with other ulcer medications to treat duodenal ulcers. It is in a class of medications called antibacterial agents. It works by preventing the growth and spread of Helicobacter pylori bacteria, which often occurs with ulcers. Treating this infection keeps ulcers from coming back.
Related Packages: 49884-0151-54Last Updated: 04/14/2024
MedLinePlus Full Drug Details: Bismuth, Metronidazole, and Tetracycline
Product Information
| NDC | 49884-0151 |
|---|---|
| Product ID | 49884-151_ae026767-f65e-4c73-98c7-16eadbe42000 |
| Associated GPIs | |
| GCN Sequence Number | 062462 |
| GCN Sequence Number Description | bismuth/metronid/tetracycline CAPSULE 125-125 MG ORAL |
| HIC3 | D4F |
| HIC3 Description | ANTI-ULCER-H.PYLORI AGENTS |
| GCN | 98238 |
| HICL Sequence Number | 020019 |
| HICL Sequence Number Description | COLLOIDAL BISMUTH SUBCITRATE/METRONIDAZOLE/TETRACYCLINE HCL |
| Brand/Generic | Generic |
| Proprietary Name | Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 140; 125; 125 |
| Active Ingredient Units | mg/1; mg/1; mg/1 |
| Substance Name | BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE |
| Labeler Name | Par Pharmaceutical, Inc. |
| Pharmaceutical Class | Bismuth [CS], Bismuth [EPC], Nitroimidazole Antimicrobial [EPC], Nitroimidazoles [CS], Tetracycline-class Antimicrobial [EPC], Tetracyclines [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA205770 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49884-0151-54 (49884015154)
| NDC Package Code | 49884-151-54 |
|---|---|
| Billing NDC | 49884015154 |
| Package | 120 CAPSULE in 1 CARTON (49884-151-54) |
| Marketing Start Date | 2023-03-07 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 4.46872 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis